Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Clinical Impact of Chronic Low-Grade Nausea Is Woefully Underestimated

November 1st 2017

Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era.

Dr. Pothuri on PARP Inhibitors for Ovarian Cancer

October 30th 2017

Bhavana Pothuri, MD, an associate professor in the Department of Obstetrics and Gynecology at NYU Langone's Perlmutter Cancer Center, discusses PARP inhibitors for the treatment of patients with ovarian cancer.

FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer

October 27th 2017

The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.

FDA Approval Sought for Maintenance Rucaparib in Ovarian Cancer

October 10th 2017

A supplemental new drug application has been submitted to the FDA for rucaparib as maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Molecular Techniques Help Identify Ovarian Cancer Recurrence

September 29th 2017

Peter Dottino, MD, discusses the utilization of molecular methods to identify ovarian cancer following treatment with chemotherapy, and how this type of research impacts the field going forward.

Testing Beyond BRCA a Growing Approach in Ovarian Cancer Families

September 21st 2017

Ophira Ginsburg, MD, discusses hereditary ovarian cancer, the occasional reluctance in testing, multigene panels, and the understanding of variants of uncertain significance.

Expert Highlights Immunotherapy Potential in Ovarian Cancer

September 19th 2017

Dmitriy Zamarin, MD, PhD, discusses immunotherapy for patients with ovarian cancer.

PARP Inhibitors Have Potential to Benefit Larger Patient Populations in Ovarian Cancer

September 19th 2017

Bhavana Pothuri, MD, discusses the available PARP inhibitors and ongoing trials further investigating these agents in ovarian cancer.

Dr. Ginsburg on Genetic Testing in Ovarian Cancer Families

September 19th 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.

Dr. Dottino on Molecular Detection of Recurrent Ovarian Cancer

September 18th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Precision Medicine Rapidly Being Incorporated Into Ovarian Cancer Care

September 18th 2017

Douglas A. Levine, MD, shared his insight on how the ovarian cancer landscape has developed a more personalized treatment approach.

Combined Niraparib and Bevacizumab Shows Promising Activity in Recurrent Ovarian Cancer

September 12th 2017

The combination of bevacizumab plus niraparib demonstrated clinical activity in women with relapsed, platinum-sensitive epithelial ovarian cancer and had a manageable toxicity profile.

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer

September 10th 2017

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, and medical director of the Nordic Society of Gynecologic Oncology-Clinical Trial Unit, discusses phase I results of a trial exploring the combination of niraparib (Zejula) and bevacizumab (Avastin) in patients with platinum-sensitive epithelial ovarian cancer.

Dr. Ledermann on Phase III ARIEL3 Results in Ovarian Cancer

September 9th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the phase III results of the ARIEL3 trial in ovarian cancer during the 2017 ESMO Congress.

Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes

September 8th 2017

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.

Dr. Barber on SCORPION Trial in Ovarian Cancer

September 6th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses the importance of the SCORPION trial in ovarian cancer.

BRCA1/2 Mutation Genetic Status Linked With Platinum Resistance in Breast and Ovarian Cancers

August 31st 2017

Katherine Nathanson, MD, discusses how the genetics of BRCA1/2-associated tumors impacts tumor development in breast and ovarian cancer and response to treatment.

Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer

August 29th 2017

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer

August 17th 2017

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

FDA Approves Olaparib Tablets for Ovarian Cancer

August 17th 2017

The FDA has approved olaparib tablets as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.